Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Multi-Specialty Research Associates

Neither a doctor nor a teaching hospital

Research payments

$1,776,467

136 payments

Through program year 2025, Multi-Specialty Research Associates is reported as receiving $1,776,467 in research payments, across 136 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $90,362 33
2024 Research $73,111 9
2023 Research $248,665 2
2022 Research $137,952 75
2021 Research $851,666 10
2020 Research $355,794 5
2019 Research $18,918 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Abbott Laboratories $1,684,439 125 payments
  2. Braintree Laboratories, Inc. $50,339 8 payments
  3. Biogen, Inc. $22,772 1 payment
  4. Teva Pharmaceuticals USA, Inc. $18,918 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Clinical Evaluation of the Investigational ID NOW COVID-19 Assay $775,986 8 payments
  2. Clinical Evaluation of the Creatinine Test with Untrained Operators in CLIA Waived Environments using Venous Specimens on the i-STAT Crea Cartridge $386,617 77 payments
  3. Accuracy of Results Obtained by Untrained Operators in CLIA-Waived Environments Using the Afinion HbA1c Dx Test for Diabetes Mellitus (REACH-DM) $307,469 2 payments
  4. ISM2504007A--Clinical Evaluation of the i-STAT Crea, CG4+ and CG8+ Carridges using Neonatal Capillary Whole Blood Specimens with the i-STAT 1 Analyzer $90,362 33 payments
  5. Id Now Covid-19 $75,680 2 payments
  6. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $50,339 8 payments
  7. Clinical Evaluation of the Panbio COVID-19 Ag AnTigen (Ag) Assay in Symptomatic Subjects (CATSS) $48,326 3 payments
  8. A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) $22,772 1 payment
  9. A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma $18,918 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record